Retro-prospective Observational Study on Risk of Progression in CP-CML Patients Eligible for TKI Discontinuation

NCT04621851 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 260

Last updated 2025-07-29

No results posted yet for this study

Summary

The purpose of this study is to investigate the safety profile of TKI discontinuation in clinical practice, with particular regard on the risk of progression after treatment discontinuation.

Conditions

  • Chronic Myeloid Leukemia

Sponsors & Collaborators

  • University of Milano Bicocca

    lead OTHER

Principal Investigators

  • Elisabetta Abruzzese, MD · Ospedale S. Eugenio Roma

  • Vincenzo Accurso, MD · A.U. Policlinico "Paolo Giaccone" Palermo

  • Mario Annunziata, MD · Azienda Ospedaliera di Rilievo Nazionale "A. Cardarelli" Napoli

  • Francesco Passamonti, MD · Ospedale di Circolo e Fondazione Macchi Varese, ASST dei Sette Laghi Varese

  • Massimo Bonifacio, MD · Istituti Ospitalieri di Verona- Policlinico G.B. Rossi Verona

  • Giovanni Caocci, MD · CTMO - Ospedale "Businco" Cagliari

  • Francesca Lunghi, MD · Ospedale Milano S. Raffaele Milano

  • Chiara Elena, MD · Fondazione IRCCS Policlinico San Matteo di Pavia

  • Monica Crugnola, MD · Az Ospedaliera Universitaria Parma

  • Sara Galimberti, MD · Azienda Ospedaliera Pisana Pisa

  • Alessandra Iurlo, MD · Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano Milano

  • Luciano Levato, MD · Az. Ospedaliera Pugliese - Ciaccio (AOPC) Catanzaro

  • Maria Cristina Miggiano, MD · Azienda ULSS 8 "Berica" Ospedale San Bortolo Vicenza

  • Patrizia Pregno, MD · A.O. Città della Salute e della Scienza di Torino S. G.Battista Torino

  • Davide Rapezzi, MD · Ospedale Cuneo

  • Rosaria Sancetta, MD · Ospedale dell'Angelo Mestre Venezia

  • Fabio Stagno, MD · P.O. Gaspare Rodolico, Catania

  • Luigia Luciano, MD · Azienda Ospedaliera Universitaria-Università degli Studi di Napoli "Federico II"

  • Carmen Fava, MD · A.S.O. Ordine Mauriziano, P.O. Umberto I Torino

  • Philipp leCoutre, MD · Charité University of Berlin · Medical Department, Division of Oncology and Hematology

  • Susanne Saussele, MD · University of Mannheim

  • Sarit Assouline, MD · Jewish General Hospital

  • Alberto Álvarez-Larrán, MD · University Hospital Clínic de Barcelona

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-30
Primary Completion
2021-09-30
Completion
2023-08-14

Countries

  • Canada
  • Germany
  • Italy
  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04621851 on ClinicalTrials.gov